Engineered Mesenchymal Stem Cell Circuits for Targeted Cancer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current combinatorial immunotherapy approaches for cancer, such as ovarian cancer, face challenges in delivering multiple therapies simultaneously to achieve maximal efficacy without significant side effects and determining appropriate dosing and timing, and are limited by the tumor microenvironment's immunosuppressive mechanisms.
Innovation Solution
Engineered cell circuits, specifically in mesenchymal stem cells, that deliver multiple immunomodulatory effector molecules to the tumor microenvironment, optimizing promoters, linkers, and signal peptides to enhance cancer therapy while minimizing systemic toxicity, and are designed to selectively home to tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple immunomodulatory effector molecules are delivered simultaneously to achieve maximal efficacy, then anti-tumor immune response is enhanced, but systemic toxicity increases
Solution Approach 1:
The patent employs tumor-specific promoters (such as TERT, survivin, or telomerase promoters) that are activated only in tumor cells, enabling the immunomodulatory effector molecules to be expressed and delivered locally at the tumor site while remaining inactive in healthy tissues. This spatial differentiation of molecular activity achieves high local efficacy while minimizing systemic toxicity.
Solution Approach 2:
The patent uses engineered mesenchymal stem cells (MSCs) as intermediary carriers that home to the tumor microenvironment and serve as localized factories for producing and secreting multiple immunomodulatory effector molecules. These MSC intermediaries deliver the therapeutic molecules directly to the tumor site, concentrating the immune-modulating effect locally while reducing systemic exposure and associated toxicity.
2Reliability
If multiple therapies are administered systemically to achieve robust anti-tumor activity, then treatment efficacy is improved, but determining appropriate dosing and timing becomes complex
Solution Approach 1:
The patent combines multiple immunomodulatory effector molecules (such as cytokines, chemokines, or immune checkpoint inhibitors) into a single genetic construct delivered by one engineered MSC population. This merging of multiple therapeutic agents into a unified delivery system eliminates the need to separately optimize dosing and timing for each molecule, as all effects are co-delivered in a coordinated manner directly to the tumor microenvironment.
Solution Approach 2:
The engineered MSCs serve as universal carriers capable of delivering multiple different types of immunomodulatory effector molecules simultaneously. This multi-functional delivery platform allows a single cell population to perform the role of multiple separate therapies, simplifying the overall treatment regimen while maintaining robust anti-tumor activity through the combined effects of the delivered molecules.
3Reliability
If tumor microenvironment is targeted to overcome immunosuppression, then anti-tumor immune response is enhanced, but tumor heterogeneity and complexity increase treatment difficulty
Solution Approach 1:
The patent segments the complex tumor microenvironment targeting strategy into multiple distinct immunomodulatory effector molecules, each addressing a specific aspect of tumor immunosuppression. For example, some MSCs are engineered to secrete cytokines that activate immune cells, while others deliver checkpoint inhibitors to block suppressive signals. This segmentation of the therapeutic approach allows systematic addressing of different immunosuppressive mechanisms within the heterogeneous tumor microenvironment.
Solution Approach 2:
The patent employs a composite therapeutic approach by combining multiple types of immunomodulatory effector molecules (cytokines, chemokines, antibodies, or small molecules) within the same engineered MSC delivery system. This composite strategy creates a multifaceted intervention that simultaneously addresses various components of the complex tumor microenvironment, overcoming immunosuppression through synergistic interactions among the different delivered molecules.
Data Source
AI summary
Provided herein are methods and compositions for dynamically controlling and targeting multiple immunosuppressive mechanisms in cancer. Some aspects provide cells engineered to produce multiple effector molecules, each of which modulates a different immunosuppressive mechanisms of a tumor, as well as methods of using the cells to treat cancer, such as ovarian, breast, or colon cancer.